Clinical Trial Update: A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab alone or with an experimental agent (BMS-986205) with or without BCG in BCG-unresponsive bladder cancer; the study status is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urinary Bladder Neoplasms

Drugs mentioned

• BCG (Bacillus Calmette-Guérin) (Bacillus Calmette-Guérin)
• BMS-986205 (BMS-986205)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Urinary Bladder Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2023-06-01